So what you want to do is you want to drive those towards the more wound healing-type. And we have data suggesting that we can do that with our dexamethasone constructs. So we can perturb the macrophages and drive them in one direction or the other. And with that, the world is kind of our oyster, and almost every disease is touched by the macrophage, or the macrophage plays a central or critical role. So that’s my spiel. Hopefully, I addressed your question, Mike.
Unidentified Analyst: You did an excellent answer. So my follow-up on that is an observation that I can make, and maybe you can’t opine on it. But I think it’s opening up the IND that will really open this up to the world. And on that, do you have any other guideline you can give us into 2024 on your target range for that IND?
Michael Rosol: Yes, sorry. Thanks. I think that’s still our goal and our objective. Obviously, it will be really helped — will have significant help propelling us forward with full funding, but that is still an achievable goal because we’ve advanced some of these significantly in the preclinical space. And what you want to do to get towards that IND, the other kind of 2 dominoes that need to fall, roughly speaking or at a high level, are you need to establish that in preclinical models that your construct or your therapy is safe and tolerated, and there are some specific studies you have to do for that. But they’re very well known and established and we can box those out, and we’ve already accounted for those in our time line.
And then the other thing you have to do is show that you can actually make the drug in a scalable fashion and it’s reliable and safe to be injected. And so those are the other 2 dominoes that need to fall. It’s fairly reasonable for us, we think, to get to those in the time lines you’ve seen with the caveat always we need to be resourced properly.
Operator: And the next question is a follow-up from Edward English, a private investor.
Edward English: Again, Dr. Rosol, I’m curious, I’ve noticed in what’s available to us in the public and the securities and exchange filings that there haven’t been any stocks granted to the Board of Directors since late November. I haven’t seen any Form 4s. Has something changed with the compensation for the Board? Are they now receiving cash? Or can you elaborate on what’s changed? And if so, why?
Michael Rosol: Go on, Erika, please.
Erika Eves: Yes. So in late 2021, the directors adopted a compensation plan for the next 12 months. Due to our funding situation, many of the directors have chosen to defer compensation until we achieve full funding. And so I can’t really speak for the Board, but I believe that, that may have had something to do with their decision to not award themselves an additional package this year. I think that they are probably waiting until we feel like they don’t have to defer any longer.
Alexander Cappello: Actually, several months ago, all of us were — had cash payments suspended. So we’ve all been working several months without compensation and some for the whole year.
Edward English: Next question, a follow-up, and that will be my question for the day. You still have the third-party assessment for the use of the tilmanocept in the RA program. It’s still out on the site, and it has revenue projections that are quite appealing. And I’m just curious if you all still stand by those projections. I think there’s some $41 million in revenue projected for the year 2024. Have those projections slipped or changed in any way?
